Xoma Royalty Corporation (XOMA)

5/1/26 not sure what STIFEL's problem is w/ their focus list, but 3/18 they had both $LGND and $JAZZ with a pt of 230 for both of them. at the time of their writing, jazz was at 181.37 but 5/1/26 it is at 202.30 and LGND was at 211 on 3/18, and as of 5/1 it is at 233.48 (so it is above its pt! but they wrote about it on 4/27 and raised pt from 230 to 255 XOMA Solidifies a Unique Position in Biotech Royalty Aggregation and Development-Stage Assets; Raise TP to $255 $XOMA 40.92 on 5/1 but buyout price is ONLY 39.00

$XOMA sell the news

$TSBX Ligand Pharmaceuticals Incorporated (Nasdaq: $LGND) and $XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), both biotechnology royalty aggregators, today announced that the companies have entered into a definitive agreement under which Ligand will acquire XOMA Royalty for $39.00 per share of common stock in cash, for a total equity value of approximately $739 million. XOMA Royalty stockholders are expected to separately receive one non-transferable Contingent Value Right (“CVR”) per share entitling the holder to receive a portion of 75% of the net proceeds that may result from certain pending litigation at XOMA Royalty.

$XOMA (+6.9% pre) $LGND Ligand to buy XOMA Royalty (Nasdaq: XOMA) in $739M ($39/sh) cash and CVR deal https://ooc.bz/l/100070

$LGND $XOMA Ligand Pharmaceuticals to acquire Xoma Royalty for c. USD 740mln

$XOMA Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator https://www.globenewswire.com/news-release/2026/04/27/3281479/0/en/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligand-s-position-as-a-leading-biopharma-royalty-aggregator.html $39.00 per share plus a CVR

$LGND buys $XOMA for $740M cash, boosting its drug royalty portfolio to 200+ medicines and spreading investment risk. https://notreload.xyz/xy/ligand-to-acquire-xoma-royalty-for-740m/

$XOMA popcorn

$XOMA 52 week scan breakout found this one...breaking over previous ATH on volume...will be looking for consolidation or pullback to get long. Only recent news I'm seeing is some analyst downgrades but $19 target.

Unicycive Therapeutics (Nasdaq: $UNCY ) announced that the company is scheduled to participate in the 25th Annual Needham Virtual Healthcare Conference. Shalabh Gupta, M.D., Chief Executive Officer, will present on Wednesday, April 15, 2026, at 3:45 p.m. ET. Unicycive is a B2i Digital Featured Company. See the full profile here: https://b2idigital.com/unicycive A link to the live and archived webcast is available on the Unicycive website under the Investors section: Events and Presentations. See the press release at https://ir.unicycive.com/news/detail/121/unicycive-therapeutics-to-present-at-the-25th-annual Unicycive Therapeutics is a clinical-stage biotechnology company developing novel treatments for kidney diseases. The company’s lead investigational treatment, oxylanthanum carbonate, is a novel phosphate-binding agent for treating hyperphosphatemia in patients with chronic kidney disease who are on dialysis and is currently under review by the U.S. Food and Drug Administration. Its second program, UNI-494, targets conditions related to acute kidney injury and has received FDA orphan drug designation for preventing delayed graft function in kidney transplant patients. Led by CEO Dr. Shalabh Gupta, MD and a seasoned executive team including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is committed to addressing unmet needs in kidney disease treatment. Learn more about Unicycive Therapeutics at https://ir.unicycive.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UNCY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of UNCY or any security, and it is not intended to offer any opinion on UNCY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $XOMA, $RMTI, $LNTH, $XBI

$XOMA Share Price: $33.16 Contract Selected: Sep 18, 2026 $30 Calls Buy Zone: $5.10 – $6.30 Target Zone: $8.73 – $10.68 Potential Upside: 62% ROI Time to Expiration: 168 Days | Updates via https://fxcapta.com/stockinfo/

$XOMA RSI: 79.41, MACD: 1.0621 Vol: 1.56, MA20: 27.47, MA50: 26.40 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$XOMA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.27 up 160.00% YoY • Reported revenue of $13.76M up 57.87% YoY

$XOMA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.27 up 160.00% YoY • Reported revenue of $13.76M up 57.87% YoY • XOMA expects income from VABYSMO and Day One royalties to increase in future periods based on projected sales, though VABYSMO's increase rate may slow. Operating expenses, including consulting and legal costs, may increase in 2026.

$XOMA Current Stock Price: $26.03 Contracts to trade: $25.0 XOMA Mar 20 2026 Call Entry: $0.10 Exit: $0.18 ROI: 78% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

$XOMA RSI: 43.13, MACD: -0.9474 Vol: 1.36, MA20: 25.29, MA50: 26.60 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$XOMA Share Price: $24.02 Contract Selected: Sep 18, 2026 $30 Calls Buy Zone: $0.89 – $1.10 Target Zone: $1.65 – $2.02 Potential Upside: 75% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/

$XOMA XOMA Royalty; biotech royalty aggregator; business model provides diversified, non-dilutive revenue stream; valuation hinges on acquired royalty portfolios and cost of capital.

$XOMA I believe 🗣️

$XOMA Announces Closing of Tender Offer and Completed Acquisition of $GBIO https://www.globenewswire.com/news-release/2026/02/09/3234655/7281/en/XOMA-Royalty-Announces-Closing-of-Tender-Offer-and-Completed-Acquisition-of-Generation-Bio-Inc.html GBIO will remain halted. Shareholders will receive $4.2913 and one CVR for each share held.

$XOMA why does it say it’s down 20%?